Skip to main content

Roth MKM Sticks to Its Buy Rating for Sensus Healthcare (SRTS)

Tipranks - Tipranks - Fri May 16, 2025

Roth MKM analyst Jason Wittes reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $4.66.

Confident Investing Starts Here:

Wittes covers the Healthcare sector, focusing on stocks such as Allurion Technologies, Globus Medical, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 3.2% and a 49.42% success rate on recommended stocks.

Sensus Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, which is a 168.24% upside from current levels. In a report released on May 14, Lake Street also maintained a Buy rating on the stock with a $13.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Sensus Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.07 million and a net profit of $1.55 million. In comparison, last year the company earned a revenue of $12.57 million and had a net profit of $4.21 million

Read More on SRTS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).